Pharma industry keeps wary eye on huge EU policy revision

A comprehensive revision of the EU’s industry policy for pharma is underway in Brussels, with firms like Leo Pharma and Lundbeck looking closely over politicians’ shoulders. Former political advisors expect a complicated, technical, but above all else, political battle, one MEP says.

Photo: AJ Vaccines

Brussels – As Europe winds down for the summer, something is picking up speed in Brussels.

The revision of central elements of the EU’s industry policy for the pharmaceutical sector is expected in the fall, an undertaking that is already garnering attention from Danish pharmaceutical firms and regulators.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs